A monoclonal anti-idiotypic antibody specific to a human IgG 1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor; a method for the production of the aforementioned monoclonal anti-idiotypic antibody by the steps of immunizing an animal with a human IgG 1 type monoclonal antibody specific to nicotinic acetylcholine receptor, collecting antibody-producing cells from the animal, fusing the collected cells with neoplastic cells, selecting from the product of fusion a hybridoma capable of producing a monoclonal anti-idiotypic antibody specific to the human IgG 1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor, propagating the selected hybridoma thereby giving rise to said monoclonal anti-idiotypic antibody, and collecting the produced monoclonal anti-idiotypic antibody; and use of the monoclonal anti-idiotypic antibody as a reagent and as an adsorbent.
A monoclonal anti-idiotypic antibody specific to a human IgG1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor; a method for the production of the aforementioned monoclonal anti-idiotypic antibody by the steps of immunizing an animal with a human IgG1 type monoclonal antibody specific to nicotinic acetylcholine receptor, collecting antibody-producing cells from the animal, fusing the collected cells with neoplastic cells, selecting from the product of fusion a hybridoma capable of producing a monoclonal anti-idiotypic antibody specific to the human IgG1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor, propagating the selected hybridoma thereby giving rise to said monoclonal anti-idiotypic antibody, and collecting the produced monoclonal anti-idiotypic antibody; and use of the monoclonal anti-idiotypic antibody as a reagent and as an adsorbent.
Specific Interference with the Determination of the Tumour-Associated Glycoprotein 72 by Human Anti-Idiotypic Antibodies Formed after Treatment with the Anti-Tumour-Associated Glycoprotein 72 Antibody ...
Two mouse monoclonal anti-anti-idiotopic antibodies (anti-anti-Id, Ab3), AF14 and AF52, were prepared by immunizing BALByc mice with rabbit polyclonal antiidiotypic antibodies (anti-Id, Ab2) raised against antibody D1.3 (Ab1) specific for the antigen hen egg lysozyme. AF14 and AF52 react with an internal image monoclonal mouse anti-Id antibody E5.2 (Ab2), previously raised against D1.3, with affinity constants (1.0 3 109 M21 and 2.4 3 107 M21, respectively) usually observed in secondary responses against protein antigens. They also react with the antigen but with lower affinity (1.8 3 106 M21 and 3.8 3 106 M21). This pattern of affinities for the anti-Id and for the antigen also was displayed by the sera of the immunized mice. The amino acid sequences of AF14 and AF52 are very close to that of D1.3. In particular, the amino acid side chains that contribute to contacts with both antigen and anti-Id are largely conserved in AF14 and AF52 compared with D1.3. Therapeutic immunizations against different
Neuroblastoma treatment with chimeric anti-disialoganglioside GD2 antibody ch14.18 showed objective anti-tumor responses. Production of anti-idiotypic antibodies (Ab2) against ch14.18 (Ab1) in some cases was positively correlated with a more favorable prognosis. According to Jernes network theory, a subset of anti-idiotypic antibodies (Ab2beta) form an internal image of the antigen and induce antibodies (Ab3) against the original antigen. The molecular origin of the anti-idiotypic antibody response in tumor patients was not investigated previously. To clone anti-idiotypic antibodies, B-cells of a ch14.18-treated neuroblastoma patient with Ab2 serum reactivity were used to construct antibody phage display libraries (Methods described in Arthritis Rheum. 2000, 43:2722-2732). Upon repetitive selection of lambda and kappa Fab-phage display libraries on target antigens ch14.18 and the murine equivalent 14G2a, positive binders were enriched. Selected Ab2-clones GK2 and GK8 as well as another 38 ...
Results Anti-infliximab antibodies were detected in 21 patients (median: 131 ng/ml, range 10-200 ng/ml). Infliximab levels were weak in 25 patients (median: 0.16 microg/ml, range: ,0.1-0.41 microg/ml). In 20/25 patients (80%), the weak level of infliximab was associated to the presence of anti-infliximab antibodies. Interestingly, in sera of two patients obtained more than one year after the last infliximab perfusion, anti-infliximab antibodies were still present. Elevated infliximab levels were associated to the presence of anti-infliximab antibodies in only one patient. In 6 patients, the loss of infliximab response was not explained by the presence of anti-TNF antibodies or weak infliximab levels, suggesting that a switch to another biological agent could be more efficient than to another TNF inhibitor.. ...
Rose, L M.; Goldman, M; and Lambert, P, "The production of anti-idiotypic antibodies and of idiotype- -anti-idiotype immune complexes after polyclonal activation induced by bacterial lps." (1982). Subject Strain Bibliography 1982. 2727 ...
B-cell lymphomas express surface immunoglobulin (immunoglobulin) containing unique idiotypic (idiotype) determinants which may be exploited as tumor specific markers. The inventor has produced murine monoclonal antibodies (MAbs) reactive with the idiotype marker derived from 67 patients with low grade, follicular, small cleaved cell lymphoma. Out of 199 monoclonal antibodies, 47 (24%) were found to react with pooled normal human serum immunoglobulin in concentrations ranging from 0.6 μg/ml to 160 μg/ml. Of these 40 monoclonal antibodies, 90% cross-reacted with idiotype present in normal serum in levels |50 μg/ml. Thirty-two of these anti-idiotypes were directed against a shared idiotope expressed on another patients lymphoma cells. The frequency of shared idiotope expression defined by each antibody ranged from 0.26% to 3.9% of the B-cell lymphomas tested. A panel of five anti-idiotype antibodies reacted with 80% of AIDS associated lymphomas. Based on the reactivity with these monoclonal antibodies,
Immunogenicity of Protein-315 and its Fab fragment (Fab-315) for isologous and heterologous strains of mice was investigated by comparing the characteristics of the anti-idiotypic response produced in BALB/c and A/J mice. The ability of these anti-idiotypic antisera to compete with DNP-lys for the ligand-binding site of Protein-315 were analyzed by comparing their hapten inhibition curves.. The anti-idiotypic responses of BALB/c mice to Protein-315 and to Fab-315 were similar to one another with regard to antibody specificity and sensitivity to inhibition by hapten, suggesting that both forms were equally immunogenic in inbred BALB/c mice. This observation indicates that the Fc portion of Protein-315 is not essential for the induction of anti-idiotypic response. Both BALB/c and A/J mice recognized the same antigenic determinants on Fab-315 since the anti-idiotypic antibodies produced by these animals were indistinguishable with regard to their interaction with Protein-315, Fv-315, and ...
Anti-idiotype vaccination represents an innovative approach to target tumor-associated antigen-expressing cells. This approach comes directly from Jernes idiotypic network theory, which postulates that due to the huge potentiality for diversity of the immunoglobulin variable regions, the idiotype repertoire can mimic the universe of self and foreign epitopes [1].. NeuGc-containing gangliosides are attractive targets for cancer immunotherapy because these glycolipids are non-self antigens in humans [2, 3]. In contrast, they have been detected in different human tumors by antibodies and chemical analysis [4-6]. Recent experimental data suggest that N-glycolyl-GM3 ganglioside (NeuGcGM3) is relevant for tumor biology [7].. mAb-1E10 [8] is an IgG1 anti-idiotype (Ab2) mAb obtained by immunizing Balb/c mice with mAb-P3 (Ab1) [9] coupled to keyhole limpet hemocyanin (KLH) in the presence of Freunds adjuvant. This Ab2 inhibited the binding of mAb-P3 to NeuGcGM3 ganglioside. mAb-1E10 induced an ...
Understanding the molecular mechanisms of immunological memory assumes importance in vaccine design. We had earlier hypothesized a mechanism for the maintenance of immunological memory through the operation of a network of idiotypic and anti-idiotypic antibodies (Ab2). Peptides derived from an internal image carrying anti-idiotypic antibody are hypothesized to facilitate the perpetuation of antigen specific T cell memory through similarity in peptide-MHC binding as that of the antigenic peptide. In the present work, the existence of such peptidomimics of the antigen in the Ab2 variable region and their similarity of MHC-I binding was examined by bioinformatics approaches. The analysis employing three known viral antigens and one tumor-associated antigen shows that peptidomimics from Ab2 variable regions have structurally similar MHC-I binding patterns as compared to antigenic peptides, indicating a structural basis for memory perpetuation. (C)) 2007 Elsevier Inc. All rights reserved.. ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
TY - JOUR. T1 - The physiology of anti-idiotypic interactions. T2 - From clonal to paratopic selection. AU - Greally, John M.. PY - 1991. Y1 - 1991. N2 - On theoretical and experimental grounds, it has been proposed that the idiotypes of immunoglobulins and of T cell receptors are composed of multiple paratopes, as opposed to a single paratope and several idiotopes. This necessitates a revision of some of the basic principles of anti-idiotypic reactions. It is also possible to infer the presence of the same or similar paratopes on different idiotypes. A paratope cannot therefore be regarded as restricted to or unique on an idiotype. For these reasons, the perception of immunological specificity in terms of clonal units is misleading. This review proposes instead that the physiological unit of immunological specificity and regulation is the paratope. This essential alteration in the perception of the immune system is referred to as paratopic selection. The approach is assessed in terms of ...
Antibodies directed against IgG and DNA are found in the sera of autoimmune MRL/Mp lpr/lpr mice. Little is known of the molecular mechanisms underlying expression of such autoantibodies. We have investigated the binding diversity and pattern of VH gene expression in a panel of murine anti-IgG antibodies. We constructed eight hybridoma clones secreting IgM antibodies that bound to mouse IgG by using spleen cells from MRL/Mp lpr/lpr mice varying in age from 4 to 15 wk; one clone was derived from a 32-wk-old MRL +/+ mouse. The monoclonal IgM products exhibited varying binding specificities for intact mouse IgG, fragments of mouse IgG [Fc, Fab, (Fab)2], and heterologous IgG. Two of these antibodies crossreacted with B and/or Z DNA. Probes from seven of eight identified mouse VH gene families (7183, S107, Q52, J558, J606, 36-60, and 3609) were hybridized under high-stringency conditions with cytoplasmic RNA blots from each clone. Six clones hybridized only with the probe from the five-member 36-60 ...
Injections may be a helpful add-on treatment for certain people with severe allergic asthma. Learn more about how it works, how much it costs, and some of the potential side effects.
E. S. Aleksandrova, F. Koralewski, M. I. Titov, A. V. Demin, A. N. Ignatova, A. V. Kozyr, A. V. Kolesnikov, A. Tramontano, S. Paul, D. Thomas, A. G. Gabibov, A. Friboulet ...
Cosenza, H; Augustin, A; and Julius, M H., "Induction and characterization of autologous anti-idiotypic antibodies." (1977). Subject Strain Bibliography 1977. 3483 ...
A 13-amino-acid motif in the cytoplasmic domain of FcyRIIB modulates B-cell receptor signalling. Nature (London) 368, 7 0 - 7 3 . , and Lamoyi, E. (1981). Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: Possible application to vaccine production. Clin. Immunol. Immunopathol. 21, 397. Noelle, R. J . , and Snow, E. C. (1991). T helper cell-dependent B cell activation. FASEB J. 5, 2770-2776. Nossal, G. J. V. (1994). Negative selection of lymphocytes. Cell 76, 2 2 9 - 2 3 9 . Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 262, 1011-1018. Finkelman, F. , Holmes, J . , Katona, I. , Urban, J. F . , Beckmann, M. , Park, L. , Schooley, K. , Coffman, R. L . , Mosmann, T. , and Paul, W. E. (1990). Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8, 3 0 3 - 3 3 3 . Fiorentino, D. F . , Bond, M. , and Mossman, T. R. (1989). Two types of mouse helper T cell. IV. Th2 clones ...
Results 33 children (22 male) aged 5-16 years were commenced on omalizumab. At 16 weeks there were significant improvements in mini-AQLQ; ACT; FENO; maintenance OCS dose; severe exacerbations and UHCVs.. 20/33 (60.6%) children continued omalizumab beyond the initial 16 weeks (up to 192 weeks). Compared to those who discontinued, at baseline these children had higher mini-AQLQ (4.28 vs. 3.05) and ACT (11 vs. 8), were younger (11 vs. 13 years) and were more likely to have been admitted to hospital (57.9% vs. 0%) and have had a severe exacerbation (95% vs. 50%) in the 16 weeks before starting omalizumab. Maximal reduction in number of exacerbations and hospital admissions was evident at 32 weeks; this was maintained for up to 144 weeks (Figure 1).. ...
Human Anti-Golimumab Antibody, clone AbD25455 is an anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug goli
|strong|Human Anti-Nivolumab Antibody, clone AbD30255|/strong| is a paratope specific, inhibitory anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug nivolumab. The antib…
Our laboratory is developing cancer vaccines that are being evaluated in animal models for their protective activity against tumors before they are administered to cancer patients. The vaccines are composed of antibodies mimicking tumor antigens (anti-idiotypic antibodies) or the antigens expressed in viruses (recombinant adeno- or vaccinia-viruses) and are selected based on their high probability of inducing both humoral and cellular immune responses in patients. The animal models we have developed for preclinical evaluation of the vaccines closely mimic the condition in cancer patients. In other studies which have reached clinical trials, we are evaluating the vaccinated patients immune responses to their tumors ...
Mean serum IFX trough level was 4.4+ 4.7mg/ml in 430 samples from 122 patients. The level was significantly lower in symptomatic phase (n=73, 2.5±5.3 μg/ml) than in the asymptomatic phase (n=357, 4.9 ± 4.6μg/ml). ROC analysis determined the cut-off level was 0.93μg/ml. Patient-based analysis revealed that the trough level was lower in Group C+D (1.3±3.3μg/ml) than Group A (4.2±4.4μg/ml) and B (5.4±5.7μg/ml), whereas administration interval was significantly shorter in Group B (7.2±1.1 wk) and C+D (6.8±1.5 wk) than Group A (8.2±0.9 wk). ATI(+) was found in 18 (11.3%) of all patients. The frequency was significantly higher in Group C+D (5/10, 50%) and E (4/8, 50%) than Group A (3/75, 4%) and B (6/38, 16%). Thus, unfavorable clinical responses were associated with low trough level and positive ATI. Muitivariate analysis using logistic regression model revealed association of therapeutic failure (Group C+D and E) with female, positive ATI, and infusion reaction (IR). Moreover, ATI was ...
我們的研究主軸是利用抗體工程技術來開發新藥。這些以抗體為結構基礎的藥物,主要標的牽涉於IgE引致的過敏反應過程。我們也積極從事開發可提升抗體工程 的數種創新技術平台。其中一項研究計畫就是要發展人源化、高親和力,及對人體膜IgE分子內CεmX具結合特異性的抗體,以用來控制表現IgE的B淋巴細 胞。CεmX是張教授的研究群發現的;它是一含有具特異序列的52個氨基酸長的胜肽區段。如發展成功,anti-CεmX可與張教授發明的anti-IgE,如已在美國等國核准上市用於嚴重哮喘的omalizumab(商名Xolair),共同使用。. ...
ForteBios Anti-Murine IgG Quantitation biosensors provide a rapid method for precise quantitation of murine immunoglobulins from crude lysates and cell culture supernatants. For Determination of Antibody Concentration
Shop a large selection of products and learn more about CD4 Rat anti-Murine, Brilliant Ultraviolet 737, Clone: GK1.5, BD Horizon 50 µg; BUV737.
Rabbit Polyclonal ID4 antibody N-Term for WB. Published in 2 Pubmed References. Order this anti-ID4 antibody. | Product number ABIN2780374
Abcam provides specific protocols for Anti-gamma H2A.X (phospho S139) antibody - ChIP Grade (ab2893) : ChIP protocols, Immunoprecipitation protocols…
Anti-gamma H2A.X (phospho S139) antibody [9F3] (ab26350) has been cited in 47 publications. References for Human, Mouse, Rat, Dog, Pig in ICC, ICC/IF, IF, IHC…
The progression of this project, as well as the outcomes, will be extremely relevant to the public and scientific researchers since Severe Allergic Asthma is a common disease worldwide. AA is well documented and the public already have a great deal of understanding and so are more likely to be interested in new advances in research related to this condition. The objectives of this work package are to ...
购买我们的CENPE肽。ab45476可作为ab27470的封闭肽并经过Blocking实验验证。Abcam提供免费的实验方案,操作技巧及专业的支持。中国80%以上现货。
引用Abcams Anti-Rhodopsin抗体[1D4] (ab5417)的参考文献列表。为您列举引用本产品的发表文章,并提供信息包括论文文献数据库中的检索编号以便您搜寻文章
Methods: Consecutive patients with severe asthma disease (n=15; Group IA, pretreatment and Group IB, post-treatment) underwent omalizumab treatment. Control group was age- and sex-matched including 25 healthy in Group II. Blood samples from both the groups were taken during their first visit (Group IA and II) and then after 12 months of treatment in asthmatic patients (Group IB). Serum levels of homocysteine (Hcy), eosinophil cationic peptide (ECP), 25-hydroxyvitamin D (25(OH)D), interleukin-1β (IL-1β), soluble OX2 (sCD200) and clinical follow-up tests including fractional exhaled nitric oxide (FeNO), asthma control test (ACT), and pulmonary function tests were evaluated ...
Anti-IgE (omalizumab) has been shown to be an effective add-on therapy for patients with allergic severe asthma. In this observational study patients aged over 18 year with uncontrolled severe persistent asthma are selected for add-on therapy with omalizumab. Patients were on high dose of ICS and had a documented history of 2-6 exacerbations requiring treatment with systemic corticosteroids ( with ,15 mg/day prednisone or other medications at similar dose, for at least 3 days). The individual dose and frequency of omalizumab administration is assessed from the dosing table. Lung function tests and asthma questionnaires (ACQ, AQLQ and RQLQ) are used in the aim of assessing clinical improvement after omalizumab treatment. Induced sputum (IS) and exhaled breath condensate (EBC) are used as a simple non-invasive methods for monitoring cellular and biochemical changes in the airways. Total blood eosinophil count, IS cytology, IS and EBC periostin and IL-6 concentrations are measured. Analyses are ...
General It is not known whether Simulect use will have a long-term effect on the ability of the immune system to respond to antigens first encountered during Simulect -induced immunosuppression. Immunogenicity Of renal transplantation patients treated with Simulect and tested for anti-idiotype antibodies, 4/339 developed an anti-idiotype antibody response, with no deleterious clinical effect upon the patient. In none of these cases was there evidence that the presence of anti-idiotype antibody accelerated Simulect clearance or decreased the period of receptor saturation. In Study 2, the incidence of human anti-murine antibody (HAMA) in renal transplantation patients treated with Simulect was 2/138 in patients not exposed to muromonab-CD3 and 4/34 in patients who subsequently received muromonab-CD3. The available clinical data on the use of muromonab-CD3 in patients previously treated with Simulect suggest that subsequent use of muromonab-CD3 or other murine anti-lymphocytic antibody preparations ...
Omalizumab, a humanized monoclonal anti-IgE antibody has the potential to alter allergen processing. Recently, it has been postulated the assessment of PHA-stimulated adenosine triphosphate (ATP) activity as maker of CD4+ T cells activity in peripheral blood cells. We present the case report of a 35-year-old woman with a history of chronic idiopathic urticaria and angioedema of 8 years of development with poor response to treatment. The patient was partially controlled with cyclosporine at doses of 100 mg/12 h. However, she was still developing hives daily. Finally treatment with omalizumab was started at dose of 300 mg every 2 weeks. The patient experienced a decrease in urticarial lesions 2 days after starting therapy. We also evaluated the effects of omalizumab therapy on the activity of peripheral blood CD4+ T cells from the patient, in order to determine the potential modification of anti-IgE therapy on the process of antigen presentation-recognition. Activity of CD4+ cells by ATP release was
Rabbit anti-idiotypic antibodies were prepared by injection of specifically purified anti-p-azobenzoate antibodies (D) from individual donor rabbits. Benzoate derivatives were found to be strong inhibitors of the reactions of D with anti-D antisera. There was a close correlation between the combining affinities of the benzoate derivatives used and their effectiveness as inhibitors. Compounds tested that are chemically unrelated to benzoate were ineffective. The results indicate either that the combining site of anti-benzoate antibody is part of an important idiotypic determinant, which is sterically blocked by hapten, or that the hapten induces a conformational change which alters idiotypic determinants not involving the active site. Such conformational changes, if they occur, must be restricted since hapten has little effect on the reactions of F(ab)2 fragments of anti-benzoate antibodies with antisera directed to rabbit fragment Fab and no detectable effect on reactions with antibodies ...
anti-Immunoglobulin G, Immunoglobulin M (IgG, IgM) (Heavy & Light Chain) antibody (Alkaline Phosphatase (AP)) ABIN637975 from antibodies-online
Deterioration of asthma upon withdrawal of Xolair as demonstrated by meeting at least one of the following: *Worsening of pulmonary function tests (FEV1 ,80% predicted for height, age, and sex) and activity levels while off Xolair treatment; *Worsening of asthma exacerbations defined as doubling of inhaled steroid dose, increase in dose of oral steroids, or initiation of oral, intravenous, intramuscular, or subcutaneous (SC) steroids while off Xolair treatment; *Increased use of rescue medications while off Xolair treatment; *ER visits or unscheduled office visits for asthma that may or may not result in hospitalization while off Xolair ...
Omalizumab is a monoclonal anti-IgE antibody currently used in the treatment of chronic spontaneous urticaria (CSU) as a third-line option in cases refractory to treatment with the licensed dose of the first-line treatment or up to 4 times that dose. The introduction of omalizumab into the therapeutic arsenal for CSU brought about a real revolution in the management of this condition. However, the dose recommended in the Summary of Product Characteristics-based on the results of pivotal studies carried out as part of the approval process-is 300 mg/mo for a period of up to 6 months. In the present issue, the Catalan-Balearic working group presents a treatment algorithm to guide the use of omalizumab in the management of CSU. They discuss the various aspects of management related to the rational and evidence-based use of this drug, including candidate population, monitoring tools (Urticaria Activity Score 7 [UAS7] and Urticarial Control Test [UCT]), starting dose and dose adjustment as well as the ...
Case report: We present the case of a 48 year old woman, with severe persistent allergic asthma, despite level 4 (GINA) medical treatment, who initiated omalizumab in order to control her nocturnal symptoms and her frequent unscheduled medical visits. Before treatment and at 12 weeks: clinical evaluation with ACT was registered; lung function, FeNO, IgE and eosinophils were measured. Two-dimensional gas chromatography (GC ´GC-ToFMS) combined with headspace solid phase microextraction (HS-SPME) was applied to the untargeted study of the volatile metabolomic urine profile. ...
IL-12 R beta 1 Goat anti-Mouse, Polyclonal, R&D Systems™ 100μg; Unlabeled IL-12 R beta 1 Goat anti-Mouse, Polyclonal, R&D Systems™ Primary...
The study by Milgrom and colleagues is their second on the use of omalizumab (anti-IgE antibody) in the treatment of asthma and the third published in the past 3 months that addresses treatment with anti-IgE in large, multicenter asthma studies. Concurrent studies by Busse and colleagues (1) and Soler and colleagues (2) included , 500 adult patients aged 12 to 75 years and used medium to high-dose inhaled steroids (500 to 1200 µg/d of beclomethasone). They used a design similar to that of Milgrom and colleagues and achieved similar results in terms of steroid reduction and decreases in exacerbations. These studies, along with an earlier publication by Milgrom and colleagues (3), make a case for anti-IgE antibodies as adjunctive treatment for steroid-dependent patients with asthma. The advantages of anti-IgE over conventional therapies include once or twice-monthly subcutaneous injections and its tolerability with infrequent side effects. However, many questions remain. Although the association ...
Omalizumab - Get up-to-date information on Omalizumab side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Omalizumab
CHO-Anti-Human IgE scFv stable cell line is clonally-derived from a CHO cell line, which has been transfected with an anti-human IgE scFv gene to allow expression of the scFv. It is an example of a cell line transfected using our proprietary CBTGS gene screening and amplification system.
Gentaur molecular products has all kinds of products like :search , ICL \ anti-Human IgE Unconjugated A.P. Host Mouse \ ME-80A for more molecular products just contact us
Author(s): Markus Brede ,Ulrich Behn Subject(s): CX.3 Category: Abstract:. The talk deals with modelling a subsystem of the immune system, the so-called idiotypic network. Idiotypic networks, a concept conceived by N.K. Jerne in 1974, are functional networks of interacting antibodies and B-cells. In principle, Jernes framework provides solutions to many issues in immunology, such as immunological memory, mechanisms for antigen recognition and the question of self/non-self discrimination. Explaining the interconnection between the elementary components local dynamics, network formation and architecture, and possible modes of global system function appears to be an ideal playground of statistical mechanics. We present a simple cellular automaton model based on a graph representation of the system. From a simplified description of idiotypic interactions rules for the random evolution of networks of occupied and empty sites on these graphs are derived. In certain biologically relevant parameter ...
THURSDAY, June 8, 2017 (HealthDay News) -- For patients with a significant response to allergen challenge, omalizumab induces protective effects against early (EAR) and late allergic reactions (LAR), according to a study published online June 5 in Allergy.. Jordis Trischler, M.D., from the University Hospital Frankfurt in Germany, and colleagues determined the time course of the early (EAR) and late allergic reaction (LAR). Ten patients with a significant response to allergen challenge were treated with omalizumab. At week one, two, four, and eight, bronchial allergen provocations were repeated.. The researchers observed a significant reduction in EAR after four weeks (change in forced expiratory volume in one second [ΔFEV1], 28 versus 11 percent; P , 0.001; exhaled nitric oxide, 86 versus 53 ppb; P , 0.05), and there was a reduction in basophil activation after two weeks (CD63 expression, 79 versus 32 percent; P , 0.05). After one week there was a reduction in LAR (ΔFEV1, 26 versus 13 ...
Container/Tube:. Preferred: Green-top (lithium heparin) tube. Acceptable: Gold-top serum gel tube or Plain Red-top tube. Specimen Volume: 170 uL of plasma or serum. Stability: Keep tubes stoppered and upright at all times. Do not use samples that have been stored at room temperature for longer than 8 hours. Tightly cap and refrigerate specimens at 2° to 8°C if the assay is not completed within 8 hours. Freeze samples at or below -20°C if the sample is not assayed within 48 hours. Freeze samples only once and mix thoroughly after thawing. Collection Instructions:. Note: 1. Human anti-mouse antibodies or other heterophile antibodies may be present in patient specimens. This assay has been specially formulated to minimize the effects of these antibodies, however results from patients known to have these antibodies should be carefully evaluated.. 2. Label specimen appropriately (plasma/serum).. ...
Goat anti-Mouse IgM Secondary Antibody, HRP conjugate from Invitrogen for Western Blot, Immunocytochemistry and Immunohistochemistry applications. Supplied as 2 mL purified secondary antibody (0.8 mg/ml) in PBS with 15mg/ml BSA and no preservative; pH 7.6.